Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q1 2026 vs. Q4 2025
How the institutions holding Aligos Therapeutics, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 41 | 2 | 35 | −4 |
| Shares | 2.81M | 200.8K | 2.78M | +164.8K (+6.3%) |
| Value | $26.2M | $1.87M | $20.6M | −$3.70M (−15.2%) |
2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (7)
Institutions that held Aligos Therapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Capital Management LLC | 178,262 | $1.32M | 0.00% |
| Vanguard Fiduciary Trust Co | 28,437 | $211.3K | 0.00% |
| D. E. Shaw & Co., Inc. | 10,978 | $81.6K | 0.00% |
| Quadrature Capital Ltd | 10,822 | $80.4K | 0.00% |
| Federation des caisses Desjardins du Quebec | 950 | $7.06K | 0.00% |
| Vanguard Global Advisers, LLC | 936 | $6.95K | 0.00% |
| Fortitude Family Office, LLC | 68 | $505 | 0.00% |
Sold out (11)
Institutions that held Aligos Therapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Jane Street Group, LLC | 24,293 | $226.4K |
| Quest Partners LLC | 13,876 | $129.3K |
| Two Sigma Advisers, LP | 13,000 | $121.2K |
| DRW Securities, LLC | 11,950 | $111.4K |
| HRT Financial LP | 11,374 | $106.0K |
| NorthCrest Asset Manangement, LLC | 10,000 | $84.1K |
| FMR LLC | 4,972 | $46.3K |
| Clear Street Markets LLC | 500 | $4.66K |
| Wealth Enhancement Advisory Services, LLC | 0 | $3.50K |
| Triumph Capital Management | 135 | $1.26K |
| Citigroup Inc | 1 | $9 |
Not filed for Q1 2026 yet (2)
Institutions that held Aligos Therapeutics, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 200,395 | $1.87M |
| Global Retirement Partners, LLC | 400 | $3.73K |